1. Introduction {#sec1-medsci-07-00080}
===============

Coronary artery disease (CAD) is a complex disease resulting from the interaction of genetic and environmental factors. Traditional risk factors for atherosclerosis include obesity, hypercholesterolemia, smoking, hypertension, and hyperglycemia \[[@B1-medsci-07-00080]\]. These factors lead to an excessive accumulation of cholesterol, which results in hardening of and accumulation of thrombotic debris in the artery wall \[[@B2-medsci-07-00080]\]. The steps involved in the formation of an atherosclerotic lesion begin with an injury to the endothelial wall, after which the retention of lipid particles occurs, followed by inflammation. These steps lead to the generation of a necrotic core (containing cell debris and lipids) covered by a fibrous cap, eventually leading to the formation of an atheromatous plaque \[[@B3-medsci-07-00080]\]. Hypercholesterolemia is one of the important risk factors involved in the formation of atherosclerotic plaques \[[@B4-medsci-07-00080]\]. It has been reported that the deposition of cholesterol particles in the endothelial wall initiates the inflammatory response, which involves the activation of macrophages and lymphocytes, as well as the production of cytokines (including tumor necrosis factor-alpha, interleukin-6, and interferon-gamma) \[[@B5-medsci-07-00080]\], and enhances the development of atheroma \[[@B4-medsci-07-00080]\]. Cholesterol is pooled in the liver from the diet or from cholesterol that is synthesized by cells. The liver is the primary organ for the regulation of cholesterol homeostasis, and the low-density lipoprotein receptor (LDLR) is one of the regulating mechanisms \[[@B6-medsci-07-00080]\]. The LDLR is a transmembrane glycoprotein that plays an important role in the uptake of low-density lipoprotein (LDL) from the blood circulation in a process that is mediated by apolipoprotein B \[[@B7-medsci-07-00080],[@B8-medsci-07-00080]\]. The LDLR binds at neutral pH specifically and with a high affinity to extracellular lipoprotein particles \[[@B9-medsci-07-00080]\]. The LDLR and LDL--cholesterol complex is then brought into the cell by endocytosis \[[@B10-medsci-07-00080]\]. LDL--cholesterol is then released by the LDLR at an acidic pH for degradation by a lysosome which results in the release of free cholesterol and the return of the LDLR to the cell surface \[[@B9-medsci-07-00080]\]. Genome-wide association studies (GWASs) have discovered certain novel gene loci that reproducibly associate with diseases \[[@B11-medsci-07-00080],[@B12-medsci-07-00080],[@B13-medsci-07-00080]\], including CAD \[[@B14-medsci-07-00080],[@B15-medsci-07-00080],[@B16-medsci-07-00080],[@B17-medsci-07-00080],[@B18-medsci-07-00080],[@B19-medsci-07-00080],[@B20-medsci-07-00080]\] and atherosclerosis \[[@B21-medsci-07-00080],[@B22-medsci-07-00080]\]. Mutations in the *LDLR* gene have been reported to cause familial hypercholesterolemia \[[@B18-medsci-07-00080],[@B23-medsci-07-00080]\]. In the present study, we investigated the association of polymorphisms in the LDLR (rs5925 and rs1529729) and CAD in a cohort from the Bangalore population.

2. Subjects and Methods {#sec2-medsci-07-00080}
=======================

This project has been approved by the institutional ethics committee (IEC), Punjabi University, Patiala, project No. 268/DLS/HG. We conducted a population-based case--control study including 200 patients with clinically confirmed CAD and 200 healthy controls (HC) with no history of CAD and no familial relationship to the CAD patients. We excluded any patient with a previous history of chronic disease from this study.

2.1. Collection of Blood Samples and Clinical History {#sec2dot1-medsci-07-00080}
-----------------------------------------------------

About 3 mL of peripheral blood was collected in an EDTA-containing vial from each patient and healthy control after they completed a questionnaire. We collected information as well as an informed written consent form from both CAD patients and healthy controls regarding personal information such as name, gender, and age. Additionally, information regarding a history of sexually transmitted diseases and addiction, such as smoking and alcohol, were collected. We also collected laboratory and clinical data.

2.2. Extraction of DNA {#sec2dot2-medsci-07-00080}
----------------------

DNA was extracted from the blood using the modified glass bead method, as described in a previous study \[[@B24-medsci-07-00080]\]. The extracted DNA was dissolved in 100 μL of 10 mM Tris-Cl (pH 8.0) buffer and stored at 4 °C until use. The quality of the DNA was assessed by gel electrophoresis.

2.3. Genotyping of the LDLR Polymorphisms (rs5925 and rs1529729) {#sec2dot3-medsci-07-00080}
----------------------------------------------------------------

Gene polymorphisms were detected using allele-specific PCR (AS-PCR). AS-PCR is based on the use of sequence-specific PCR primers that allow for amplification of the template DNA when the target allele is contained within the sample. Primers were designed using primer 3 software ([Table 1](#medsci-07-00080-t001){ref-type="table"}, [Figure 1](#medsci-07-00080-f001){ref-type="fig"}). For rs5925, AS-PCR was performed in two tubes with each of the tubes containing a common forward primer and a different reverse primer. The reaction mixtures for the rs5925 AS-PCR contained template DNA, 3--4 μL (50 ng); the common forward primer, 0.3 μL (25 pmol); a reverse primer, 0.3 μL (25 pmol); Coral load dye, 2.5 μL; 12.5 μL of TopTaq Master Mix (Qiagen, Germany); and enough nuclease free ddH~2~O to bring the final volume to 25 μL. The AS-PCR for rs1529729 was performed in two tubes, each containing a different primer set. The reaction mixture for the rs152972 AS-PCR contained DNA template, 3--4 μL (50 ng); either the F1/R2 or the F2/R1 primer combinations, 0.3 μL of each primer (25 pmol); Coral load dye, 2.5μL; 12.5 μL of TopTaq Master Mix (Qiagen, Germany); and enough nuclease free ddH~2~O to bring the final volume to 25 μL. The PCR conditions used were as follows: initial denaturation for 10 min at 95 °C, 35 cycles of 30 s at 95 °C (denaturation), 30 s at 57 °C (the rs5925 AS-PCR) or 61 °C (the rs1529729 AS-PCR) (annealing), and 1 min at 72 °C (elongation), followed by 10 min at 72 °C (final elongation). The PCR products were visualized using electrophoresis via 2% agarose gel stained with ethidium bromide ([Figure 2](#medsci-07-00080-f002){ref-type="fig"}). The lengths of the PCR products for rs1529729 were 212 bp for F1/R1, and 175 bp for F2/R2 PCR products, and 176 bp for the rs5925 ([Figure 2](#medsci-07-00080-f002){ref-type="fig"}).

2.4. Statistical Analysis {#sec2dot4-medsci-07-00080}
-------------------------

Group differences were compared using a Student's two-sample *t*-test or a one-way analysis of variance (ANOVA) for continuous variables, and a Chi-square test for categorical variables. Differences in both the single nucleotide polymorphism SNP allele and in the genotype frequencies between groups were evaluated using the Chi-square test. The associations between both SNP genotypes and the risk of CAD were estimated by computing the odds ratios (ORs), risk ratios (RRs), and risk differences (RDs) with 95% confidence intervals (CIs). Allele frequencies among cases, as well as controls, were evaluated using the Chi-square test. *P* \< 0.05 was considered significant. All statistical analyses were performed using SPSS 16.0 (IBM, Chicago, IL, USA).

3. Results {#sec3-medsci-07-00080}
==========

A total of 200 CAD patients and 200 healthy controls were included in this study. The demographic characteristics of CAD patients and controls are shown in [Table 2](#medsci-07-00080-t002){ref-type="table"}. The ratios of gender and age differences in CAD patients are comparable to those of the control group. The clinical characteristics of the CAD patients are shown in [Table 3](#medsci-07-00080-t003){ref-type="table"}.

3.1. The Genotype Frequency of the LDLR Polymorphisms rs1529729 and rs5925 {#sec3dot1-medsci-07-00080}
--------------------------------------------------------------------------

The genotype frequency of the rs1529729 polymorphisms CC, CT, TT in patients were 9, 77, and 14%, respectively, whereas they were 21, 76, and 3% in controls, respectively. The differences in the proportions of the genotype frequencies were significantly different (*P* = 0.0001, [Table 4](#medsci-07-00080-t004){ref-type="table"}). The genotype frequency of the rs5925 polymorphisms GG, GA, AA in patients were 27, 62, and 11% respectively, whereas they were 15, 76, and 9% in controls, respectively. The differences in the proportions of the genotype frequencies were significantly different (*P* = 0.006, [Table 4](#medsci-07-00080-t004){ref-type="table"}).

3.2. rs1529729 C \> T and rs5925 G \> A Polymorphisms Were Associated with CAD {#sec3dot2-medsci-07-00080}
------------------------------------------------------------------------------

The results of the present study indicated that in the codominant model the CT genotype of the rs1529729 polymorphism was associated with a decreased susceptibility to CAD with an OR = 0.42 (95% CI, 0.23--0.77), RR = 0.59 (0.39--0.89), *P* = 0.0047. The TT genotype was also associated with a reduced risk for CAD with an OR = 0.09 (95% CI, 0.03--0.26), RR = 0.36 (0.24--0.55), *P* = 0.0001 ([Table 5](#medsci-07-00080-t005){ref-type="table"}). In the dominant model the CT + TT genotype was associated with a decreased susceptibility to CAD with an OR = 0.37 (95% CI, 0.21--0.67), RR = 0.56 (0.38--0.84), *P* = 0.001. The TT genotype was associated with decreased susceptibility to CAD with OR = 0.19 (95% CI, 0.076--0.47), RR = 0.57 (0.47--0.69), *P* = 0.0003 ([Table 5](#medsci-07-00080-t005){ref-type="table"}).

Our results also showed that in the codominant model the GA genotype of the rs5925 polymorphism was associated with a decreased susceptibility to CAD, OR = 0.45 (95% CI, 0.27--0.75), RR = 0.65 (0.47--0.88), *P* = 0.002. In the dominant model the GA + AA genotype was associated with a reduced risk of CAD with OR = 0.477 (95% CI, 0.28--0.78), RR = 0.66 (0.48--0.9), *P* = 0.003 ([Table 5](#medsci-07-00080-t005){ref-type="table"}). Our results also showed that covariates such as gender, age, blood levels of random sugar, total cholesterol, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were non-significantly different (*P* \> 0.05) among the genotypes of both the SNPs in the patient group. We also did not see significant effects (*P* \> 0.05) of diabetes, hypertension, intake of alcohol, smoking, and pan masala on either the rs5925 or the rs1529729 polymorphisms ([Table 6](#medsci-07-00080-t006){ref-type="table"}). These results were unexpected and might be due to the limited sample size used in this research.

4. Discussion {#sec4-medsci-07-00080}
=============

4.1. Association of rs1529729 C \> T and rs5925 G \> A Genotypes with CAD {#sec4dot1-medsci-07-00080}
-------------------------------------------------------------------------

Cardiovascular disease (CVD) represents an economic and health burden all over the world \[[@B25-medsci-07-00080]\]. CVD has become a leading cause of death in all parts of India. In India, CVD has increased by 59%, from 23.2 million (1990) to 37 million (2010) \[[@B26-medsci-07-00080]\]. One thousand and seven hundred mutations in the *LDLR* gene have been associated with familial hypercholesterolemia \[[@B23-medsci-07-00080]\], which is one of the traditional risk factors for CVD \[[@B27-medsci-07-00080]\]. This fact has prompted us to examine the association of the LDLR rs1529729 C \> T and rs5925 G \> A gene variations with CAD. Our results indicated that the rs1529729 C \> T genotype distribution is different between the cases and the control (*P*-value = 0.0001, [Table 4](#medsci-07-00080-t004){ref-type="table"}). Moreover, our results showed that the CT and TT genotypes of rs1529729 C \> T are associated with decreased susceptibility to CAD with an OR = 0.42 (95% CI, 0.23--0.77), RR = 0.59 (0.39--0.89), *P* = 0.0047, and an OR = 0.09 (95% CI, 0.03--0.26), RR = 0.36 (0.24--0.55), *P* = 0.0001, respectively ([Table 5](#medsci-07-00080-t005){ref-type="table"}). At the allelic level, the T allele is associated with a reduced susceptibility to CAD with an OR = 0.63 (95% CI, 0.47--0.83), RR = 0.79 (0.69--0.91), *P* = 0.0011 ([Table 5](#medsci-07-00080-t005){ref-type="table"}). We did not see significant differences in the random blood sugar (RBS), triglyceride, cholesterol, HDL-C, and LDL-C levels between the rs1529729 genotypes in CAD patients (*P*-value \> 0.05, [Table 6](#medsci-07-00080-t006){ref-type="table"}). This may be due to the relatively small sample size taken in this study. These results may be in good agreement with the study by Kathiresan et al., 2008 \[[@B28-medsci-07-00080]\].

The results showed that the rs5925 G \> A genotype distribution is different between the cases and the control (*P*-value = 0.006, [Table 4](#medsci-07-00080-t004){ref-type="table"}). It was indicated that the GA genotype of the rs5925 polymorphism is associated with decreased susceptibility to CAD with an OR = 0.45 (95% CI, 0.27--0.75), RR = 0.65 (0.47--0.88), *P* = 0.002. The rs5925 polymorphism (in cooperation with the rs688 polymorphism) has been shown to regulate the splicing efficiency of the *LDLR* gene \[[@B29-medsci-07-00080]\]. This result may be consistent with a study that showed that the rs5925 polymorphism is associated with the thickness of the carotid-intima media in Slovenian type 2 diabetes T2D patients \[[@B30-medsci-07-00080]\]. Furthermore, the rs5925 polymorphism has been predicted to be one of the SNPs that cause familial hypercholesterolemia in the Malaysian population \[[@B31-medsci-07-00080]\].

Our results also showed that there are no significant differences (*P* \> 0.05) between the rs5925 genotype distribution and RBS, triglycerides, cholesterol, HDL-C, and LDL-C levels ([Table 6](#medsci-07-00080-t006){ref-type="table"}). Again, these results may be due to the small sample size, or perhaps some of the CAD patients had been treated with hypolipidemic agents. LDLR is a transmembrane glycoprotein at the hepatocyte surface that plays an important role in cholesterol homeostasis \[[@B8-medsci-07-00080]\]. We suggest that the T allele of the rs1529729 polymorphism and the GA genotype of the rs5925 polymorphism protect against CAD by increasing the expression of LDLR at the hepatocyte surface such that LDL-C uptake and metabolism is enhanced. In support of this suggestion, the rs5925 polymorphism has been described as an exon-splicing enhancer \[[@B29-medsci-07-00080]\]. However, the effect of rs1529729 and rs5925 polymorphisms on LDLR expression should be to be elucidated in a future study.

To our knowledge, this is the first study that has shown the potential associations of the rs5925 and rs1529729 polymorphisms with CAD in a South Indian population. The limitations of this study include a relatively small sample size and the fact that the study population contained a high percentage of males compared to females ([Table 2](#medsci-07-00080-t002){ref-type="table"}).

4.2. The Frequency of the rs5925 and rs1529729 Polymorphisms in Different Populations {#sec4dot2-medsci-07-00080}
-------------------------------------------------------------------------------------

The frequency of the rs5925 genotypes GG, GA, and AA has been studied in different populations ([Table 7](#medsci-07-00080-t007){ref-type="table"}). The frequency of the rs1529729 genotypes CC, CT, and TT have been reported in an Iranian population as 28.43, 42.16, and 29.41%, respectively ([Table 7](#medsci-07-00080-t007){ref-type="table"}). In the present study, the rs1529729 genotype distributions were 21, 76, and 3% ([Table 7](#medsci-07-00080-t007){ref-type="table"}). This difference may be due to the different sample size or different ethnicity.

The results showed that the lowest percentage of the GG genotype in controls was (4%) in the Taiwanese population, while the highest was (56.5%) in the Chinese population ([Table 7](#medsci-07-00080-t007){ref-type="table"}). Our study found that the GG genotype in controls was 15%, which is consistent with previous findings ([Table 7](#medsci-07-00080-t007){ref-type="table"}). The GA genotype ranged from 51 to 34% in Mexican and Taiwanese populations, respectively. The GA genotype in our study was relatively high (76%). In this study, the AA genotype in the control group was 9%, which is within the range of previous findings (8 to 62%) in Chinese and Taiwanese populations, respectively ([Table 7](#medsci-07-00080-t007){ref-type="table"}).

5. Conclusions {#sec5-medsci-07-00080}
==============

Taken together, the results of the present study indicated that the CT and TT genotypes of the rs1529729 polymorphism and the GA genotype of the rs5925 polymorphism are associated with decreased susceptibility to CAD in a South Indian population. However, these results must await further validation in future studies with larger sample sizes and in different populations. Moreover, a proteomic study on the effect of the rs1529729 and rs5925 polymorphisms on the LDLR protein is recommended.

We thank the patients and the healthy control for their participation in this project.

Conceptualization, all authors; Methodology, C.K.J., R.M. and I.E.; sample collection, C.K.J. and S.B.; Investigation C.K.J., R.M., and S.B. Analyses, C.K.J., R.M. and I.E.; Validation, R.M. and S.M.S.C.; Supervision, S.M.S.C.; Visualization, all authors; Original draft preparation C.K.J.; Writing---Review and Editing I.E. and R.M.

C.K.J was funded by a scholarship from UGC.

The authors declare no conflict of interest.

![The annealing sites of the primers used for genotyping rs1529729 (**A**) and rs5925 (**B**).](medsci-07-00080-g001){#medsci-07-00080-f001}

![Genotyping of rs1529729 C \> T (**A**) and rs5925 G \> A (**B**) polymorphisms using allele-specific PCR (AS-PCR) assay.](medsci-07-00080-g002){#medsci-07-00080-f002}

medsci-07-00080-t001_Table 1

###### 

Primers sequences of allele-specific (AS)-PCR used for genotyping the low-density lipoprotein receptor (LDLR) gene polymorphisms rs1529729 and rs5925.

  SNP                                                           Primer Sequence              Product Size   T~a~
  ------------------------------ ------------------------------ ---------------------------- -------------- -------
  **rs1529729**                  F1 Forward primer (C allele)   5-GTGGTGCCATGTATAACACCC-3    175 bp         61 °C
  R1 Reverse primer              5-CAAGAACCCAAGTTTGGAAAC-3                                                  
  F2 Forward primer (T allele)   5-GTGGTGCCATGTATAACACCT-3      212 bp                                      
  R2 Reverse primer              5-CTATATCTGGAGGCAAGAACCTGA-3                                               
  **rs5925**                     Reverse primer (G allele)      5′-GGGTGAGGTTGTGGAAGACG-3′   176 bp         57 °C
  Reverse primer (A allele)      5′-GGGTGAGGTTGTGGAAGACA-3′     176 bp                                      
  Common Forward primer          5′-CAGTGTTTAACGGGATTTGT-3′                                                 

medsci-07-00080-t002_Table 2

###### 

Demographic characteristics of coronary artery disease (CAD) patients and healthy controls.

  Variables                   No. of CAD Cases (*n* = 200 (100%)   No. of Healthy Controls (*n* = 200 (100%)
  --------------------------- ------------------------------------ -------------------------------------------
  No. of cases and controls   200 (100%)                           200 (100%)
  **Gender difference**                                            
  Males                       180 (90%)                            176 (88%)
  Females                     20 (10%)                             24 (12%)
  **Age difference**                                               
  Age ≤50                     90 (45%)                             88 (44%)
  Age \>50                    110 (55%)                            112 (56%)

medsci-07-00080-t003_Table 3

###### 

Baseline characteristics of CAD patients.

  Variables                                          CAD Cases (*n* = 200)   (%)
  -------------------------------------------------- ----------------------- ---------
  **Random blood sugar (RBS)**                                               
  ≤140 mg                                            129                     (64.5%)
  \>140 mg                                           71                      (35.5%)
  **Cholesterol**                                                            
  ≤200 mg                                            176                     (88%)
  \>200 mg                                           24                      (12%)
  **High-density lipoprotein cholesterol (HDL-C)**                           
  ≤40 mg                                             166                     (83%)
  \>40 mg                                            34                      (17%)
  **Low-density lipoprotein cholesterol (LDL-C)**                            
  ≤100 mg                                            150                     (75%)
  \>100 mg                                           50                      (25%)
  **Triglycerides (TGL)**                                                    
  ≤150 mg                                            105                     (52.5%)
  \>150 mg                                           95                      (47.5%)
  **Coronary heart disease (CHD) in family**                                 
  Yes                                                15                      (7.5%)
  No                                                 185                     (92.5%)
  **Hypertension**                                                           
  Yes                                                29                      (14.5%)
  No                                                 171                     (85.5%)
  **Type 2 diabetes**                                                        
  Yes                                                39                      (19.5%)
  No                                                 161                     (80.5%)
  **Smoking**                                                                
  Yes                                                121                     (60.5%)
  No                                                 79                      (39.5%)
  **Alcohol**                                                                
  Yes                                                71                      (35.5%)
  No                                                 129                     (64.5%)
  **Pan masala**                                                             
  Yes                                                4                       (2%)
  No                                                 196                     (98%)

medsci-07-00080-t004_Table 4

###### 

The genotype frequency of the *LDLR* polymorphisms of study cohorts (controls and CAD patients).

  SNP                          Genotype                     C/C         C/T         T/T        Chi-Square   Df      *P*-Value
  ---------------------------- ---------------------------- ----------- ----------- ---------- ------------ ------- -----------
  rs1529729                    CAD patients *n* = 200 (%)   18 (9%)     154 (77%)   28 (14%)   23.85        2       0.0001
  Controls *n* = 200 (%)       42 (21%)                     152 (76%)   06 (3%)                                     
  rs5925                       Genotype                     G/G         G/A         A/A        Chi-square   Df      *P*-value
  CAD patients *n* = 200 (%)   54 (27%)                     124 (62%)   22 (11%)    10.1       2            0.006   
  Controls *n* = 200 (%)       30 (15%)                     152 (76%)   18 (9%)                                     

medsci-07-00080-t005_Table 5

###### 

Association of the *LDLR* rs1529729 C \> T and rs5925 G \> A gene variations with CAD.

  SNP              Genotypes        Healthy Controls   CAD Cases            Odds Ratio (OR) (95% CI)   Risk Ratio (RR)   *P*-Value
  ---------------- ---------------- ------------------ -------------------- -------------------------- ----------------- -----------
  **rs1529729**                     (*n* = 200)        (*n* = 200)                                                       
  **Codominant**                                                                                                         
  LDLR-CC          42               18                 **1 (ref.)**         **1 (ref.)**                                 
  LDLR-CT          152              154                0.42 (0.23--0.77)    0.59 (0.39--0.89)          0.0047            
  LDLR-TT          06               28                 0.09 (0.03--0.26)    0.36 (0.24--0.55)          0.0001            
  **Dominant**                                                                                                           
  LDLR-CC          42               18                 1 (ref.)             1 (ref.)                                     
  LDLR-(CT + TT)   158              182                0.37 (0.21--0.67)    0.56 (0.38--0.84)          0.001             
  **Recessive**                                                                                                          
  LDLR-(CC + CT)   194              172                1 (ref.)             1 (ref.)                                     
  LDLR-TT          06               28                 0.19 (0.076--0.47)   0.57 (0.47--0.69)          0.0003            
  **Allele**                                                                                                             
  LDLR-C           236              190                1 (ref.)             1 (ref.)                                     
  LDLR-T           164              210                0.63 (0.47--0.83)    0.79 (0.69--0.91)          0.0011            
  **rs5925**       **Codominant**                                                                                        
  LDLR-GG          30               54                 1 (ref.)             1 (ref.)                                     
  LDLR-GA          152              124                0.45 (0.27--0.75)    0.65 (0.47--0.88)          0.002             
  LDLR-AA          18               22                 0.67 (0.32--1.46)    0.79 (0.50--1.24)          0.322             
  **Dominant**                                                                                                           
  LDLR-GG          30               54                 1 (ref.)             1 (ref.)                                     
  LDLR-(GA+AA)     170              146                0.477 (0.28--0.78)   0.66 (0.48--0.9)           0.003             
  **Recessive**                                                                                                          
  LDLR-(GG+GA)     182              178                1 (ref.)             1 (ref.)                                     
  LDLR-AA          18               22                 1.24 (0.64--2.4)     1.12 (0.78--1.6)           0.5               
  **Allele**                                                                                                             
  LDLR-G           212              232                1 (ref.)             1 (ref.)                                     
  LDLR-A           188              168                0.8 (0.61--1.07)     0.9 (0.78--1.03)           0.107             

medsci-07-00080-t006_Table 6

###### 

Correlations of the covariates with rs5925 and rs1529729 genotypes.

  rs1529729                           rs5925                                                                              
  ----------------------------------- ----------- ----- ----- ----- ------ ---- ----------- ----- ----- ----- ------ ---- -----------
  Subjects                            *n* = 200   C/C   C/T   T/T   X^2^   DF   *P* value   G/G   G/A   A/A   X^2^   DF   *P*-value
  **Correlation with gender**                                                                                             
  Males                               180         15    138   27    2.2    2    0.33        48    111   21    0.83   2    0.66
  Females                             20          03    16    01                            06    13    01                
  **Correlation with age**                                                                                                
  Age ≤ 50                            90          07    73    10    1.61   2    0.447       23    58    09    0.43   2    0.806
  Age \> 50                           110         11    81    18                            31    66    13                
  **Correlation with RBS**                                                                                                
  RBS ≤ 140 mg                        129         13    98    18    0.52   2    0.77        33    83    13    0.87   2    0.647
  RBS \> 140 mg                       71          05    56    10                            21    41    09                
  **Correlation with cholesterol**                                                                                        
  Cholesterol ≤ 200 mg                176         14    137   25    1.96   2    0.375       45    114   17    5.33   2    0.069
  Cholesterol \> 200 mg               24          04    17    03                            09    10    05                
  **Correlation with HDL**                                                                                                
  HDL ≤ 40 mg                         166         14    128   24    0.5    2    0.778       44    104   18    0.18   2    0.913
  HDL \> 40 mg                        34          04    26    04                            10    20    04                
  **Correlation with LDL**                                                                                                
  LDL ≤ 100 mg                        150         15    113   22    1.07   2    0.5857      44    92    14    2.77   2    0.25
  LDL \> 100 mg                       50          03    41    06                            10    32    08                
  **Correlation with TGL**                                                                                                
  TGL ≤ 150 mg                        105         10    79    16    0.4    2    0.8187      25    66    14    1.95   2    0.377
  TGL \> 150 mg                       95          08    75    12                            29    58    08                
  **Correlation with hypertension**                                                                                       
  Hypertension                        29          03    22    04    0.07   2    0.9656      04    22    03    3.26   2    0.195
  No hypertension                     171         15    132   24                            50    102   19                
  **Correlation with diabetes**                                                                                           
  Diabetes                            39          04    30    05    0.13   2    0.9371      07    28    04    2.24   2    0.326
  No diabetes                         161         14    124   23                            47    96    18                
  **Correlation with CHD**                                                                                                
  CHD                                 15          02    11    02    0.37   2    0.8311      01    12    02    3.41   2    0.181
  No CHD                              185         16    143   26                            53    112   20                
  **Correlation with smoking**                                                                                            
  Smoking                             121         13    93    15    1.6    2    0.4493      26    45    08    2.32   2    0.313
  No smoking                          79          05    61    13                            28    79    14                
  **Correlation with alcohol**                                                                                            
  Alcohol                             71          8     52    11    1.01   2    0.6035      18    47    06    1.07   2    0.585
  No alcohol                          129         10    102   17                            36    77    16                
  **Correlation with pan masala**                                                                                         
  Pan masala                          04          00    04    00    1.22   2    0.5434      00    03    01    1.94   2    0.379
  No pan masala                       196         18    150   28                            54    121   21                

medsci-07-00080-t007_Table 7

###### 

The rs5925 G \> A and rs1529729 C \> T genotype distributions in different populations.

  rs5925                                                                                                                                         
  --------------- ---------------------- --------- -------------------------- ------- ------------------ ------- ----------------------- ------- ----------------------------
  **Country**     **Disease**            ***n***   **Homozygous Wild Type**   **%**   **Heterozygous**   **%**   **Homozygous Mutant**   **%**   **Reference**
  Mexico          Hypertension           160       36                         22.5    73                 45.63   51                      31.87   \[[@B32-medsci-07-00080]\]
                  Controls               160       34                         21.25   82                 51.25   44                      27.5    
  Slovenia        Type 2 diabetes        399       67                         16.8    189                47.4    143                     35.8    \[[@B30-medsci-07-00080]\]
                  Controls               196       26                         13.3    91                 46.4    79                      40.3    
  Taiwan          Ischemic stroke        815       52                         6.4     262                32.1    501                     61.5    \[[@B33-medsci-07-00080]\]
                  Controls               430       17                         4       146                34      267                     62      
  Chile           Hypercholesterolemia   116       25                         21.6    78                 67.2    13                      11.2    \[[@B34-medsci-07-00080]\]
                  Controls               NA        NA                                 NA                         NA                              
  China           Blood pressure         608       297                        48.8    237                39      74                      12.2    \[[@B35-medsci-07-00080]\]
                  Controls               616       348                        56.5    216                35.1    52                      8.4     
  Present study   CAD                    200       54                         27      124                62      22                      11      
                  Controls               200       30                         15      152                76      18                      9       
  **Country**     **Disease**            ***n***   **Homozygous Wild Type**   **%**   **Heterozygous**   **%**   **Homozygous Mutant**   **%**   **Reference**
  rs1529729                                                                                                                                      
  Iran            CAD                    170       43                         25.44   103                60.36   24                      14.2    \[[@B36-medsci-07-00080]\]
                  Controls               104       29                         28.43   44                 42.16   31                      29.41   
  Sweden          Cardiovascular         5084      1610                       31.7    2481               48.8    993                     19.5    \[[@B28-medsci-07-00080]\]
                  Controls               NA        NA                                 NA                         NA                              
  Present         CAD cases              200       18                         9       154                77      28                      14      
  study           Controls               200       42                         21      152                76      6                       3       
